Duchenne muscular dystrophy: Current cell therapies

Therapeutic Advances in Neurological Disorders

Volumn 8, Issue 4, 2015, Pages 166-177

  Sienkiewicz, Dorota ^a   Okurowska Zawada, Bozena ^a   Paszko Patej, Grazyna ^a   Kawnik, Katarzyna ^a   Kulak, Wojciech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Duchenne muscular dystrophy; G CSF; stem cells

Indexed keywords

ATALUREN; CORTICOSTEROID DERIVATIVE; DYSTROPHIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; PLACEBO; RETROVIRUS VECTOR;

6 MINUTE WALKING TEST; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CLINICAL ASSESSMENT TOOL; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; EMBRYONIC STEM CELL; EPIDERMAL STEM CELL; EXON SKIPPING; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE THERAPY; GENETIC DISORDER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; LIFE EXPECTANCY; LOW DRUG DOSE; MOBILIZATION; MUSCLE STEM CELL; MUSCLE STRENGTH; NEURAL STEM CELL; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SAFETY; SCOLIOSIS; STEM CELL; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; STOP CODON; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM;

EID: 84932142529     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285615586123     Document Type: Review

References (89)

1. Aoki Y. Yokota T. Nagata T. Nakamura A. Tanihata J. Saito T. et al. (2012) Bodywide skipping of exons 45–55 in dystrophic mdx 52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109:13763–13768.
2. Arechavala-Gomeza V. Anthony K. Morgan J. Muntoni F. (2012) Antisense oligo-nucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr Gene Ther 12: 152–160.
3. Bach J. Martinez D. (2011) Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care 65: 744–750.
4. Barnham K. Masters C. Bush A. (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3: 205–214.
5. Bongso A. Lee E. (2005) Stem cells: their definition, classification and sources. In: Ed. Bongso A. Lee E. (eds), Stem Cells: From Bench to Bedside, Singapore: World Scientific Publishing, pp. 1–14.
6. Braun R. Wang Z. Mack D. Childers M. (2014) Gene therapy for inherited muscle diseases: where genetics meets rehabilitation medicine. Am J Phys Med Rehabil 93: 97–107.
7. Bushby K. Muntoni F. Urtizberea A. Hughes R. Griggs R. (2004) Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids, Naarden, The Netherlands. Neuromuscul Disord 14: 526–534.
8. Carletti B. Piemonte F. Rossi F. (2011) Neuroprotection: the emerging concept of restorative neural stem cell biology for the treatment of neurodegenerative diseases. Curr Neuropharmacol 9: 313–317.
9. Chen J. Sanberg P. Li Y. Wang L. Willing A. Sancez-Ramos J. et al. (2001) Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 32: 2682–2688.
10. Chien Y. (2012) Oculopharyngeal muscular dystrophy – an under-diagnosed disease in China? Report of a China-born Chinese with PABPN 1 mutation and epidemiology review of the literature. J Formos Med Assoc 111: 397–402.
11. Clement A. Nguyen M. Roberts E. Garcia M. Boillée S. Rule M. et al. (2003) Wild-type nonneuronal cells extend survival of SOD 1 mutant motor neurons in ALS mice. Science 302: 113–117.
12. Cyrulnik S. Hinton V. (2008) Duchenne muscular dystrophy: a cerebellar disorder? Neurosci Biobehav Rev 32: 486–496.
13. Demetri G. Griffin J. (1999) Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808.
14. Emery A. (2002) The muscular dystrophies. Lancet 2: 687–895.
15. Fan Y. Maley M. Beilharz M. Grundes M. (1996) Rapid death of injected myoblasts in myoblast transfer therapy. Muscle Nerve 19: 853–860.
16. Farini A. Razini P. Erratico S. Torrente Y. Meregalli M. (2009) Cell based therapy for Duchenne muscular dystrophy. J Cell Physiol 221: 526–534.
17. Farini A. Villa C. Manescu A. Fiori F. Giuliani A. Razini P. et al. (2012) Novel insight into stem cell trafficking in dystrophic muscles. Inter J Nanomed 7: 3059–3067.
18. Finkel R.S. Flanigan K.M. Wong B. Bönnemann C. Sampson J. Sweeney H.L. et al. (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PloS ONE 8 (12): e81302. doi:10.1371/journal.pone.0081302.
19. Galli R. Borello U. Gritti A. Minasi M. Bjornson C. Coletta M. et al. (2000) Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci 3: 986–991.
20. Goemans N. Tulinius M. van den Akker J. Burm B. Ekhart P. Heuvelmans N. et al. (2011) Systemic administration of PRO 051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513–1522.
21. Goritz C. Friesen J. (2012) Neural stem cells and neurogenesis in the adult. Cell Stem Cell 10: 657–659.
22. Guerette B. Skuk D. Célestin F. Huard C. Tardif F. Asselin I. et al. (1997) Prevention by anti-LFA-1 of acute myoblast death following transplantation. J Immunol 159: 2522–2531.
23. Hara M. Yausa S. Shimiji K. Onizuka T. Hayashiji N. Ohno Y. et al. (2011) G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation. J Exp Med 208: 715–727.
24. Harada M. Quin Y. Takano H. Minamino T. Zou Y. Toko H. et al. (2005) G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. J Perinat Med 11: 305–311.
25. Helderman-van den Enden A. Straathof C. Aartsma-Rus A. den Dunnen J. Verbist B. Bakker E. et al. (2010) Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 20: 251–255.
26. Hinton V. Fee R. de Vivo D. Goldstein E. (2007) Poor facial affect recognition among boys with Duchenne muscular dystrophy. J Autism Dev Disord 37: 1925–1933.
27. Hogrel J. Zagnoli F. Canal A. Fraysse B. Bouchard J. Skuk D. (2013) Assessment of a symptomatic Duchenne muscular dystrophy carrier 20 years after myoblast transplantation from her asymptomatic identical twin sister. Neuromuscul Disord 23: 575–579.
28. Huan-Tng L. Otsu M. Nakauchi H. (2012) Stem cell therapy: an exercise in patience and prudence. Philos Trans A Math Phys Eng Sci 368: 1–14.
29. Jackson K. Majka S. Wang H. Pocius J. Hartley C. Majesky M. et al. (2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107: 1395–1402.
30. Jin K. Sun Y. Xie L. Mao X. Childs J. Peel A. et al. (2005) Comparison of ischemia-directed migration of neural precursor cells after intrastriatal, intraventricular, or intravenous transplantation in rat. Neurobiol Dis 18: 366–374.
31. Kawada H. Takizawa S. Takanashi T. Marita Y. Fujita J. Fukuda K. et al. (2006) Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective forfunctional recovery facilitating proliferation of intrinsic neural stem / progenitor cells and trnsition of bone marrow-derived neuronal cells. Circulation 113: 701–710.
32. Keating A. (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell 10: 709–716.
33. Kobinger G. Louboutin J. Barton E. Sweeney H. Wilson J. (2003) Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther 14: 1441–1449.
34. Konieczny P. Swiderski K. Chamberlain J. (2013) Gene and cell mediated therapies for muscular dystrophy. Muscle Nerve 47: 649–663.
35. Lapidos K. Kakkar R. McNally E. (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94: 1023–1031.
36. Li J. Imitola J. Snyder E. Sidman R. (2006) Neural stem cells rescue nervous Purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets. J Neurosci 26: 7839–7848.
37. Liu Y. Seçkin H. Izci Y. Du Z. Yan Y. Başkaya M. (2009) Neuroprotective effects of mesenchymal stem cells derived from human embryonic stem cells in transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 29: 780–791.
38. Maffioletti S. Noviello M. English K. Tedesco F. (2014) Stem cell transplantation for muscular dystrophy: the challenge of immune response. Biomed Res Int 2014: article ID 964010.
39. McLean S. Khan W. Malik A. Anand S. Snow M. (2012) The potential of stem cells in the treatment for skeletal muscle injury and disease. Stem Cells Int 2012: article ID 282348.
40. Meirelles L. Nardi N. (2009) Methodology, biology and clinical applications of mesenchymal stem cells. Front Biosci 14: 4281–4298.
41. Mendell J. Clark K. (2006) Challenges for gene therapy for muscular dystrophy. Curr Neurol Neurosci Rep 6: 47–56.
42. Mendell J. Campbell K. Rodino-Klapac L. Sahenk Z. Shilling C. Lewis S. et al. (2010) Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429–1437.
43. Mendell J. Rodino-Klapac L. Sahenk Z. Malik V. Kaspar B. Walker C. et al. (2012) Gene Therapy For Muscular Dystrophy: Lessons Learned And Path Forward. Neurosci Lett 527: 90–99.
44. Meng J. Adkin C. Rechavala-Gomeza V. Boldrin L. Muntoni F. Morgan J. (2010) The contribution of human synovial stem cells to skeletal muscle regeneration. Neuromuscul Disord 20: 6–15.
45. Meng J. Muntoni F. Morgan J. (2011) Stem cells to treat muscular dystrophies – where are we? Neuromuscul Disord 21: 4–12.
46. Mercuri E. Muntoni F. (2013) Muscular dystrophies. Lancet 381: 845–860.
47. Metcalf D. (2008) Hematopoietic cytokines. Blood 111: 485–491.
48. Mezey E. Chandross K. Harta G. Maki R. McKercher S. (2000) Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 290: 1779–1782.
49. Miller R. Sharma K. Pavlath G. Gussoni E. Mynhier M. Lanctot A. et al. (1997) Myoblast implantation in Duchenne muscular dystrophy: the San Francisco Study. Muscle Nerve 20: 469–478.
50. Moxley R.T. 3rd. Pandya S. Ciafaloni E. Fox D.J. Campbell K. (2010) Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25: 1116–1129.
51. Mueller M. Bialleck H. Bomke B. Brauniger S. Varga C. Seidl C. (2012) Safety and efficacy of healthy volunteer stem cell mobilization with filgastrim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang 104: 1–9.
52. Muntoni F. (2010) The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAD-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 20: 355–362.
53. Muntoni F. Wells D. (2007) Genetic treatments in muscular dystrophies. Curr Opin Neurol 20: 590–594.
54. Nallamilli B. Ankala A. Hegde M. (2014) Molecular diagnosis of Duchenne muscular dystrophy. Curr Protoc Hum Genet 1: 1–9.
55. Okada H. Takemura G. Li Y. Ohno T. Li L. Maruyama R. et al. (2008) Effect of a long-term treatment with a low-dose granulocyte colony-stimulating factor on post-infarction process in the heart. J Cell Mol Med 12: 1272–1283.
56. Orlic D. Kajstura J. Chimenti S. Jakoniuk I. Anderson S. Li B. et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701–705.
57. Osawa M. Hanada K. Hamada H. Nakauchi H. (1996) Long-term lympho-hematopoietic reconstitution by a single CD-34-low/negative hematopoetic stem cell. Science 273: 242–245.
58. Ourednik J. Ourednik V. Lynch W. Schechner M. Synder E. (2002) Neural stem cell display an inherent mechanism for rescuing dysfunctional neurons. Nature Biotechnol 20: 1103–1110.
59. Pane M. Scalise R. Berardinelli A. D'Angelo G. Ricotti V. Alfieri P. et al. (2013) Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul Disord 23: 451–455.
60. Parkinson E. (1992) Epidermal keratinocyte stem cells: their maintenance and regulation. Semin Cell Biol 3: 435–444.
61. Partridge T. (2004) Stem cell therapies for neuromuscular diseases. Acta Neurol Belg 104: 141–147.
62. Périé S. Trollet C. Mouly V. Vanneaux V. Mamchaoui K. Bouazza B. et al. (2014) Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I / IIa clinical study. Mol Ther 22: 219–225.
63. Pluchino S. Quattrini A. Barambilla E. Gritti A. Salani G. Dina G. et al. (2003) Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422: 688–694.
64. Price F. Kuroda K. Rudnicki M. (2007) Stem cell based therapies to treat muscular dystrophy. Biochim Biophys Acta 1772: 272–283.
65. Pune M. Lombardo M. Alfieri P. D'Amico A. Bianco F. Vasco G. et al. (2012) Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr 161: 705–709.
66. Qu-Petersen Z. Deasy B. Jankowski R. Ikezawa M. Cummins J. Pruchnic R. et al. (2002) Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157: 851–864.
67. Ra J. Shin I. Kim S. Kang S. Kang B. Lee H. et al. (2011) Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cell Dev 20: 1297–1308.
68. Ricotti V. Ridout D. Scott E. Quinlivan R. Robb S. Manzur A. et al. (2013) Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84: 698–705.
69. Ruozi B. Belletti D. Bondioli L. de Vita A. Forni F. Vandelli M. et al. (2012) Neurotrophic factors and neurodegenerative diseases: a delivery issue. Int Rev Neurobiol 102: 207–247.
70. Schneider A. Kruger T. Steigleder D. Weber C. Pitzer C. Laage R. et al. (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115: 2083–2098.
71. Shafritz D. Oertel M. Menthena A. Nierhoff D. Dabeva M. (2006) Liver stem cells and prospects for liver reconstitution by transplanted cells. Hepatology 43: 89–98.
72. Shapiro F. Zurakowski D. Bui T. Darras B.T. (2014) Progression of spinal deformity in wheelchair-dependent patients with Duchenne muscular dystrophy who are not treated with steroids: coronal plane (scoliosis) and sagittal plane (kyphosis, lordosis) deformity. Bone Joint J 96: 100–105.
73. Sharma A. Sane H. Badhe P. Gokulchandran N. Kulkarni P. Lohiya M. et al. (2013) A clinical study shows safety and efficacy of autologous bone marrow mononuclear cell therapy to improve quality of life in muscular dystrophy patients. Cell Transplant 22(Suppl. 1): S127–S138.
74. Sharma A. Sane H. Paranjape A. Bhagawanani K. Gokulchandran N. Badhe P. (2014) Autologous bone marrow mononuclear cell transplantation in Duchenne muscular dystrophy – a case report. Am J Case Rep 15: 128–134.
75. Sienkiewicz D. Kułak W. Okurowska-Zawada B. Paszko-Patej G. Dmitruk E. Kalinowska A. et al. (In press) Beneficial effects of granulocyte colony-stimulating factor therapy for facioscapulohumeral dystrophy. Neuromuscul Disord.
76. Simões G. Oliveira A. (2010) Alfa motoneurone input changes in dystrophic MDX mice after sciatic nerve transection. Neuropathol Appl Neurobiol 36: 55–70.
77. Simões G. Oliveira A. (2012) Granulocyte-colony stimulating factor improves MDX mouse response to peripheral nerve injury. PloS ONE 7: e42803.
78. Simões G. Benitez S. Oliveira A. (2014) Granulocyte colony-stimulating factor (G-CSF) positive effects on muscle fiber degeneration and gait recovery after nerve lesion in MDX mice. Brain Behav 4: 738–753.
79. Skuk D. Tremblay J. (2013) Myoblast transplantation in skeletal muscle. In: Ed. Atala A. Lanza R. (eds), Handbook of Stem Cells, 2nd edn, Volume 2: Adult and Fetal Stem Cells. London: Academic Press, Chapter 57, pp. 653–664.
80. Skuk D. Goulet M. Tremblay J. (2006) Use of repeating dispensers to increase the efficiency of the intramuscular myogenic cell injection procedure. Cell Transplant 15: 659–663.
81. Stratos I. Rotter R. Epiel C. Mittlemeier T. Vollmar B. (2007) Granulocyte-colony stimulating factor anhances muscle proliferation and strenght following skeletal muscle injury in rats. J Appl Physiol 103: 1857–1863.
82. Tedesco F. Dellavalle A. Diaz-Manera J. Messina G. Cossu G. (2010) Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 120: 11–19.
83. Teng Y. Lavik E. Qu X. Park K. Ourednik J. Zurakowski D. et al. (2002) Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U S A 99: 3024–3030.
84. Theise N. Badve S. Saxena R. Henegariu O. Sell S. Crawford J. et al. (2000) Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 31: 235–240.
85. Toma J. Akhavan M. Fernandes K. Barnabé-Heider F. Sadikot A. Kaplan D. et al. (2001) Isolation of multipotent adult stem cells from the dermis of mammalin skin. Nat Cell Biol 3: 778–784.
86. Touznik A. Lee J. Yokota T. (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14: 809–819.
87. Uccelli A. Benvenuto F. Laroni A. Giunti D. (2011) Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 24: 59–64.
88. Young H. Duplaa C. Romero-Ramos M. Chesselet M. Vourc'h P. Yost M. et al. (2001) Human reserve pluripotent mesenchymal stem cells are present in the connective issue of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec 264: 51–62.
89. Zaruba M. Theiss H. Vallaster M. Mehl U. Brunner S. David R. et al. (2009) Strategy between cd26/Dpp-IV inhibition and G-CSF improves cardiac function after acute myocardial infaction. Cell Stem Cell 4: 313–323.